Aerpio initiates clinical trial of AKB-9778 for treatment of PAOG
Category: #health  By Pankaj Singh  Date: 2019-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aerpio initiates clinical trial of AKB-9778 for treatment of PAOG

A US-based pharmaceutical company, Aerpio Pharmaceuticals, Inc., recently announced the initiation of Phase 1b clinical trial of AKB-9778 to develop treatment of PAOG (primary open angle glaucoma), report sources.

For the record, Aerpio Pharmaceuticals is a biopharmaceutical company that design compounds that activate Tie2 for treatment of ocular diseases & complications of diabetes. Tie2 is a central regulator of vascular stability and in patients with diabetes & other conditions, down-regulation of Tie2 has been observed. The down-regulation is caused by activation of 2 inhibitors of Tie2: Ang-2 and VE-PTP. AKB-9778 is the company’s leading compound and is being investigated in topical ocular formulation to determine its potential in treatment of primary open angle glaucoma.

As per sources close to the matter, the Phase 1 study will enroll 4 cohorts of 12 subjects & the study is a double-masked and multiple-ascending dose trial. The subjects will receive a placebo or increasing daily doses of topical ocular formulation of AKB-9778. The main endpoint of the trial is ocular tolerability & safety, with intraocular pressure lowering as the key pharmacodynamic endpoint.

Kevin Peters, M.D. & Chief Scientific Officer of Aerpio Pharmaceuticals was reportedly quoted saying that primary open angle glaucoma is characterized by increased intraocular pressure (IOP) leading to neuroretina and optic nerve anomalies. The only clinical approach shown to slow down or prevent vision loss is by reducing IOP. The conventional outflow pathway that consists of specialized vessel Schlemm’s canal & a trabecular meshwork, controls intraocular pressure and has been identified as the site of increased resistance to aqueous humor outflow in primary open angle glaucoma.

In a recent study on animal models, it has been observed that suitable ocular dosing of AKB-9778 lowers intraocular pressure, through its action on Schlemm’s canal & in two sequential Phase 2 clinical studies, it has been observed that medical administration of AKB-9778 significantly reduced intraocular pressure in ocular normotensive patients.

Based on the data collected, it can be concluded that AKB-9778 could provide a differentiated approach to treating primary open angle glaucoma. The company is looking forward to sharing the results of this study by the end of 2019, Peters added.

Source credits: http://ir.aerpio.com/phoenix.zhtml?c=254540&p=irol-newsArticle&ID=2401008

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Unacademy takes over live game streaming platform Rheo TV
Unacademy takes over live game streaming platform Rheo TV
By Pankaj Singh

Unacademy, an Indian educational technology company, has recently announced the purchase of Rheo TV, a live game streaming platform focused on making professional game streaming a mainstream career choice in India. Launched in August 2019, Rheo...

Byju's acquires Epic to strengthen footprint in North America
Byju's acquires Epic to strengthen footprint in North America
By Pankaj Singh

Byju's, a major Ed-tech company based in India, has reportedly taken over Epic, a US-based digital reading platform for kids, in a $500 million deal, with plans to enter the lucrative international market. The acquisition comes over three months...

Razorpay acquires TERA Finlabs to reinforce B2B credit infrastructure
Razorpay acquires TERA Finlabs to reinforce B2B credit infrastructure
By Pankaj Singh

The acquisition aligns with Razorpay’s goal to develop affordable credit solutions for underbanked small businesses Razorpay, a fintech startup based in India, has recently announced the acquisition of TERA Finlabs, a Bengaluru-based startup w...